NASDAQ:CKPT Checkpoint Therapeutics - CKPT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $5.67 +0.20 (+3.66%) (As of 02/8/2023 12:00 AM ET) Add Compare Share Share Today's Range$5.40▼$5.6750-Day Range$0.52▼$7.7352-Week Range$3.56▼$24.10Volume84,162 shsAverage Volume253,416 shsMarket Capitalization$52.73 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Checkpoint Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside702.5% Upside$45.50 Price TargetShort InterestHealthy4.27% of Float Sold ShortDividend StrengthN/ASustainability-0.63Upright™ Environmental ScoreNews Sentiment0.21Based on 4 Articles This WeekInsider TradingSelling Shares$102,359 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.91) to ($4.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.42 out of 5 starsMedical Sector147th out of 1,026 stocksPharmaceutical Preparations Industry57th out of 504 stocks 3.5 Analyst's Opinion Consensus RatingCheckpoint Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $45.50, Checkpoint Therapeutics has a forecasted upside of 702.5% from its current price of $5.67.Amount of Analyst CoverageCheckpoint Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.27% of the float of Checkpoint Therapeutics has been sold short.Short Interest Ratio / Days to CoverCheckpoint Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Checkpoint Therapeutics has recently decreased by 13.33%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCheckpoint Therapeutics does not currently pay a dividend.Dividend GrowthCheckpoint Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCheckpoint Therapeutics has received a 62.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Checkpoint Therapeutics is -0.63. Previous Next 2.3 News and Social Media Coverage News SentimentCheckpoint Therapeutics has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Checkpoint Therapeutics this week, compared to 1 article on an average week.Search Interest9 people have searched for CKPT on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Checkpoint Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Checkpoint Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $102,359.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Checkpoint Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Checkpoint Therapeutics are expected to grow in the coming year, from ($5.91) to ($4.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Checkpoint Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Checkpoint Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCheckpoint Therapeutics has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Checkpoint Therapeutics (NASDAQ:CKPT) StockCheckpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.Read More Receive CKPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CKPT Stock News HeadlinesFebruary 5, 2023 | americanbankingnews.comWilliam Garrett Gray Sells 3,154 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) StockFebruary 5, 2023 | americanbankingnews.comJames F. Oliviero III Sells 10,261 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) StockFebruary 9, 2023 | Tradewins (Ad)New Years, New Ways To Trade!If you’ve been considering options trading but don’t know where to start, trading champion Chuck Hughes’ coveted guide, “Options Trading Made Easy” is for you! Free for a limited time, this guide could help 2023 become your most profitable year yet! Click here for a free copy now! February 1, 2023 | marketwatch.comImmune Checkpoint Blockers Market: Prosperous Growth Opportunities 2023 with Business Expansion Plans, Top Players Forecast to 2027January 18, 2023 | marketwatch.comGlobal Immune Checkpoint Inhibitors Market Size 2023 with End-user Industries, Segments Covered in the Report, Report Contains (113) PagesJanuary 17, 2023 | benzinga.comCheckpoint Therapeutics to Participate in the B. Riley Securities' 3rd Annual Oncology ConferenceJanuary 10, 2023 | seekingalpha.comCheckpoint Therapeutics: An Updated AnalysisJanuary 4, 2023 | finance.yahoo.comCheckpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell CarcinomaFebruary 9, 2023 | Vantage Point (Ad)3 Secrets To Consistent Trading SuccessDon't get caught in the trap of standing on the sidelines of intermarket correlation. The truth is that it’s impossible for you (or any human) to visualize and calculate complicated intermarket causations. Learn with A.I. which global markets have the most influence on a target market. Save a Seat for This Free Live Training. January 1, 2023 | finance.yahoo.comIndividual investors in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) are its biggest bettors, and their bets paid off as stock gained 36% last weekDecember 24, 2022 | msn.comCitations, arrest made following RPD's DUI/Driver's License Checkpoint on ThursdayDecember 23, 2022 | usnews.comPakistan Suicide Car Bombing Kills One Police Official, Injures OthersDecember 6, 2022 | marketwatch.comCheckpoint Therapeutics Shares Dive 10% on Pending 1-for-10 Reverse SplitDecember 5, 2022 | finance.yahoo.comCheckpoint Therapeutics Announces Reverse Stock SplitNovember 8, 2022 | finance.yahoo.comCheckpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate HighlightsNovember 7, 2022 | benzinga.comSensei Biotherapeutics to Host Virtual Key Opinion Leader Webinar, "Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint"November 4, 2022 | marketwatch.comCheckpoint Inhibitors for Treating Cancer Market 2022-2026 Competition to Heat up With Innovative Technologies Going Mainstream GloballyNovember 2, 2022 | usnews.comPalestinian Shot Dead in Car-Ramming Attack at West Bank CheckpointOctober 26, 2022 | msn.comPreston County Sobriety Checkpoint planned for NovemberSeptember 17, 2022 | nasdaq.comWe're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn RateSeptember 8, 2022 | seekingalpha.comCheckpoint: Strong Data, But Comes With RisksSeptember 7, 2022 | bizjournals.comCheckpoint Surgical names new CEO as founder Len Cosentino steps asideAugust 26, 2022 | msn.comBurbank Police to Set Up DUI Checkpoint on Saturday NightAugust 16, 2022 | bizjournals.comWaltham biotech Checkpoint Therapeutics stops cancer study due to Ukraine warAugust 12, 2022 | marketwatch.comCheckpoint Swings to 2Q Loss, Ends Trial Due to War in UkraineAugust 9, 2022 | marketwatch.comImmune Checkpoint Inhibitors Market Trends 2022 Sales, Top Vendors, Growth Insights, Segments, Size, Industry Share and Forecast to 2029July 19, 2022 | marketwatch.comGlobal Immune Checkpoint Inhibitors Market 2022 Opportunity Analysis, Comprehensive Insights, CAGR Status and Future Opportunity Assessment by 2028See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CKPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CKPT Company Calendar Last Earnings11/04/2021Today2/08/2023Next Earnings (Estimated)3/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CKPT CUSIPN/A CIK1651407 Webwww.checkpointtx.com Phone(781) 652-4500FaxN/AEmployees14Year FoundedN/APrice Target and Rating Average Stock Price Forecast$45.50 High Stock Price Forecast$76.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+164.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($8.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-56,670,000.00 Net Margins-53,252.24% Pretax Margin-53,252.24% Return on Equity-508.89% Return on Assets-187.37% Debt Debt-to-Equity RatioN/A Current Ratio0.94 Quick Ratio0.94 Sales & Book Value Annual Sales$270,000.00 Price / Sales195.30 Cash FlowN/A Price / Cash FlowN/A Book Value$3.43 per share Price / Book1.65Miscellaneous Outstanding Shares9,300,000Free Float8,902,000Market Cap$52.73 million OptionableNot Optionable Beta1.49 Key ExecutivesJames F. OlivieroPresident, Chief Executive Officer & DirectorWilliam Garrett GrayChief Financial Officer, Secretary & TreasurerJaclyn JaffeHead-Investor RelationsKey CompetitorsNextCureNASDAQ:NXTCAbeona TherapeuticsNASDAQ:ABEOProMIS NeurosciencesNASDAQ:PMNLipocineNASDAQ:LPCNSensei BiotherapeuticsNASDAQ:SNSEView All CompetitorsInsiders & InstitutionsEnvestnet Asset Management Inc.Sold 68,036 shares on 2/7/2023Ownership: 0.299%Emfo LLCSold 183,455 shares on 2/2/2023Ownership: 0.084%James F Oliviero IIISold 10,261 sharesTotal: $48,944.97 ($4.77/share)William Garrett GraySold 3,154 sharesTotal: $15,107.66 ($4.79/share)Ironwood Investment Management LLCSold 126,339 shares on 1/31/2023Ownership: 0.135%View All Insider TransactionsView All Institutional Transactions CKPT Stock - Frequently Asked Questions Should I buy or sell Checkpoint Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CKPT shares. View CKPT analyst ratings or view top-rated stocks. What is Checkpoint Therapeutics' stock price forecast for 2023? 2 brokers have issued twelve-month price targets for Checkpoint Therapeutics' shares. Their CKPT share price forecasts range from $15.00 to $76.00. On average, they predict the company's share price to reach $45.50 in the next year. This suggests a possible upside of 702.5% from the stock's current price. View analysts price targets for CKPT or view top-rated stocks among Wall Street analysts. How have CKPT shares performed in 2023? Checkpoint Therapeutics' stock was trading at $5.11 on January 1st, 2023. Since then, CKPT shares have increased by 11.0% and is now trading at $5.67. View the best growth stocks for 2023 here. When is Checkpoint Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023. View our CKPT earnings forecast. How were Checkpoint Therapeutics' earnings last quarter? Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.14) EPS for the quarter, meeting analysts' consensus estimates of ($0.14). The firm earned $0.03 million during the quarter, compared to the consensus estimate of $0.30 million. Checkpoint Therapeutics had a negative trailing twelve-month return on equity of 508.89% and a negative net margin of 53,252.24%. What other stocks do shareholders of Checkpoint Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Kadmon (KDMN) and Rigel Pharmaceuticals (RIGL). What is Checkpoint Therapeutics' stock symbol? Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT." Who are Checkpoint Therapeutics' major shareholders? Checkpoint Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Park Avenue Securities LLC (0.50%), Envestnet Asset Management Inc. (0.30%), Ironwood Investment Management LLC (0.14%), Emfo LLC (0.08%), Bartlett & Co. LLC (0.05%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James F Oliviero III and William Garrett Gray. View institutional ownership trends. How do I buy shares of Checkpoint Therapeutics? Shares of CKPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Checkpoint Therapeutics' stock price today? One share of CKPT stock can currently be purchased for approximately $5.67. How much money does Checkpoint Therapeutics make? Checkpoint Therapeutics (NASDAQ:CKPT) has a market capitalization of $52.73 million and generates $270,000.00 in revenue each year. The company earns $-56,670,000.00 in net income (profit) each year or ($8.70) on an earnings per share basis. How can I contact Checkpoint Therapeutics? Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.checkpointtx.com. The company can be reached via phone at (781) 652-4500 or via email at investor@chimerareit.com. This page (NASDAQ:CKPT) was last updated on 2/9/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.